These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 23062115

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Synergistic effect of iontophoresis and chemical enhancers on transdermal permeation of tolterodine tartrate for the treatment of overactive bladder.
    Prasanthi D, Lakshmi PK.
    Int Braz J Urol; 2013; 39(1):63-75; discussion 76. PubMed ID: 23489517
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Studies on the preparation, characterization and pharmacological evaluation of tolterodine PLGA microspheres.
    Sun F, Sui C, Teng L, Liu X, Teng L, Meng Q, Li Y.
    Int J Pharm; 2010 Sep 15; 397(1-2):44-9. PubMed ID: 20600717
    [Abstract] [Full Text] [Related]

  • 9. Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum.
    Liu X, Fu L, Dai W, Liu W, Zhao J, Wu Y, Teng L, Sun F, Li Y.
    Int J Pharm; 2014 Aug 25; 471(1-2):322-31. PubMed ID: 24882035
    [Abstract] [Full Text] [Related]

  • 10. Production of extended release mini-tablets using directly compressible grades of HPMC.
    Mohamed FA, Roberts M, Seton L, Ford JL, Levina M, Rajabi-Siahboomi AR.
    Drug Dev Ind Pharm; 2013 Nov 25; 39(11):1690-7. PubMed ID: 23078551
    [Abstract] [Full Text] [Related]

  • 11. Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin.
    Sathyan G, Dmochowski RR, Appell RA, Guo C, Gupta SK.
    Clin Pharmacokinet; 2004 Nov 25; 43(14):1059-68. PubMed ID: 15530134
    [Abstract] [Full Text] [Related]

  • 12. Drug release-modulating mechanism of hydrophilic hydroxypropylmethylcellulose matrix tablets: distribution of atoms and carrier and texture analysis.
    Park JB, Lim J, Kang CY, Lee BJ.
    Curr Drug Deliv; 2013 Dec 25; 10(6):732-41. PubMed ID: 23855499
    [Abstract] [Full Text] [Related]

  • 13. Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder.
    Olsson B, Szamosi J.
    Clin Pharmacokinet; 2001 Dec 25; 40(2):135-43. PubMed ID: 11286323
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response.
    Ellsworth PI, Borgstein NG, Nijman RJ, Reddy PP.
    J Urol; 2005 Oct 25; 174(4 Pt 2):1647-51; discussion 1651. PubMed ID: 16148673
    [Abstract] [Full Text] [Related]

  • 16. Interaction between fed gastric media (Ensure Plus®) and different hypromellose based caffeine controlled release tablets: comparison and mechanistic study of caffeine release in fed and fasted media versus water using the USP dissolution apparatus 3.
    Franek F, Holm P, Larsen F, Steffansen B.
    Int J Pharm; 2014 Jan 30; 461(1-2):419-26. PubMed ID: 24342711
    [Abstract] [Full Text] [Related]

  • 17. Oral controlled release formulations of rifampicin. Part II: Effect of formulation variables and process parameters on in vitro release.
    Hiremath PS, Saha RN.
    Drug Deliv; 2008 Jan 30; 15(3):159-68. PubMed ID: 18379928
    [Abstract] [Full Text] [Related]

  • 18. Development of Sustained Release System Based on High Water-Absorbable Gel Formation Using Croscarmellose Sodium, Alkaline Excipients and HPMC (ACSH SR System); Novel Application of Croscarmellose Sodium as a Gel Former.
    Gomi M, Mizutani N, Senoo R, Matsubara N, Watanabe A, Maruyama M, Kimura G, Higaki K.
    Pharm Res; 2023 Dec 30; 40(12):3073-3086. PubMed ID: 37964084
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
    Malhotra B, Darsey E, Crownover P, Fang J, Glue P.
    Br J Clin Pharmacol; 2011 Aug 30; 72(2):226-34. PubMed ID: 21352267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.